Bayer Says Sandoz, Accord Will Infringe UK Xarelto Patent
Bayer has claimed that two rival drugmakers, Sandoz and Accord, plan on releasing generic blood-thinning treatments that will infringe a key U.K. patent for its best-selling drug Xarelto, shortly after the...To view the full article, register now.
Already a subscriber? Click here to view full article